Eszter Tichy

Cost-effectiveness of adding carfilzomib to lenalidomide and dexamethasone in relapsed multiple myeloma from a US perspective

Andrzej Jakubowiak, Marco Campioni, Ágnes Benedict et al. · Journal of Medical Economics · 2016 · 51 citations · Full text

Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI)

Thitima Kongnakorn, Christian Eckmann, Matteo Bassetti et al. · Antimicrobial Resistance and Infection Control · 2019 · 19 citations · Full text

Cost-effectiveness analysis of ceftazidime/avibactam compared to imipenem as empirical treatment for complicated urinary tract infections

Thitima Kongnakorn, Florian Wagenlehner, Marco Falcone et al. · International Journal of Antimicrobial Agents · 2019 · 17 citations · Full text

Cost-effectiveness Analysis, Resistant Pathogens, Pharmacotherapy +16

Cost-effectiveness Comparison of Ceftazidime/Avibactam Versus Meropenem in the Empirical Treatment of Hospital-acquired Pneumonia, Including Ventilator-associated Pneumonia, in Italy

Eszter Tichy, Antoní Torres, Matteo Bassetti et al. · Clinical Therapeutics · 2020 · 17 citations · Full text

Economic burden of antimicrobial resistance and inappropriate empiric treatment in Thailand

Thitima Kongnakorn, Eszter Tichy, Kirati Kengkla et al. · Antimicrobial Stewardship & Healthcare Epidemiology · 2023 · 11 citations · Full text